{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "KRW", "marketState": "PREPRE", "regularMarketChangePercent": -0.73664826, "regularMarketPrice": 5390.0, "exchange": "KOE", "shortName": "KAINOSMED", "longName": "Kainos Medicine, Inc.", "exchangeTimezoneName": "Asia/Seoul", "exchangeTimezoneShortName": "KST", "gmtOffSetMilliseconds": 32400000, "market": "kr_market", "esgPopulated": false, "regularMarketTime": 1683873029, "sharesOutstanding": 5401000, "fiftyDayAverage": 6413.6, "fiftyDayAverageChange": -1023.6001, "fiftyDayAverageChangePercent": -0.15959837, "twoHundredDayAverage": 5437.725, "twoHundredDayAverageChange": -47.725098, "twoHundredDayAverageChangePercent": -0.008776666, "marketCap": 29111390208, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1591660800000, "priceHint": 2, "regularMarketChange": -40.0, "regularMarketDayHigh": 5560.0, "regularMarketDayRange": "5270.0 - 5560.0", "regularMarketDayLow": 5270.0, "regularMarketVolume": 80949, "regularMarketPreviousClose": 5430.0, "bid": 5390.0, "ask": 5460.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "KOSDAQ", "financialCurrency": "KRW", "regularMarketOpen": 5310.0, "averageDailyVolume3Month": 131385, "averageDailyVolume10Day": 67232, "fiftyTwoWeekLowChange": 3595.0, "fiftyTwoWeekLowChangePercent": 2.0027854, "fiftyTwoWeekRange": "1795.0 - 13200.0", "fiftyTwoWeekHighChange": -7810.0, "fiftyTwoWeekHighChangePercent": -0.59166664, "fiftyTwoWeekLow": 1795.0, "fiftyTwoWeekHigh": 13200.0, "symbol": "284620.KQ"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "29, Dunchon-daero 541beon-gil", "address2": "3rd Floor Jungwon-gu", "city": "Seongnam-si", "zip": "13216", "country": "South Korea", "phone": "82 2 567 7419", "fax": "82 2 552 1470", "website": "https://www.kainosmedicine.com", "industry": "", "sector": "", "longBusinessSummary": "Kainos Medicine, Inc. researches and develops various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug. Kainos Medicine, Inc. was incorporated in 2007 and is headquartered in Seongnam-si, South Korea.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Ki-Sub  Lee", "age": 72, "title": "Chairperson, Co-Founder & CEO", "yearBorn": 1950, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jaemoon  Lee Ph.D.", "age": 64, "title": "Chief Bus. Officer, VP of Biology & Internal Director", "yearBorn": 1958, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. In Chull  Kim", "title": "Chief Strategic Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}